JP2010525063A5 - - Google Patents

Download PDF

Info

Publication number
JP2010525063A5
JP2010525063A5 JP2010506270A JP2010506270A JP2010525063A5 JP 2010525063 A5 JP2010525063 A5 JP 2010525063A5 JP 2010506270 A JP2010506270 A JP 2010506270A JP 2010506270 A JP2010506270 A JP 2010506270A JP 2010525063 A5 JP2010525063 A5 JP 2010525063A5
Authority
JP
Japan
Prior art keywords
virus
pharmaceutical composition
composition according
compound
immunodeficient subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010506270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010525063A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/005322 external-priority patent/WO2008133966A1/en
Publication of JP2010525063A publication Critical patent/JP2010525063A/ja
Publication of JP2010525063A5 publication Critical patent/JP2010525063A5/ja
Withdrawn legal-status Critical Current

Links

JP2010506270A 2007-04-27 2008-04-25 ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法 Withdrawn JP2010525063A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91453207P 2007-04-27 2007-04-27
PCT/US2008/005322 WO2008133966A1 (en) 2007-04-27 2008-04-25 Methods of reducing nephrotoxicity in subjects administered with nucleoside

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014233457A Division JP2015063538A (ja) 2007-04-27 2014-11-18 ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法

Publications (2)

Publication Number Publication Date
JP2010525063A JP2010525063A (ja) 2010-07-22
JP2010525063A5 true JP2010525063A5 (cg-RX-API-DMAC7.html) 2013-05-23

Family

ID=39523817

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010506270A Withdrawn JP2010525063A (ja) 2007-04-27 2008-04-25 ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法
JP2014233457A Pending JP2015063538A (ja) 2007-04-27 2014-11-18 ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014233457A Pending JP2015063538A (ja) 2007-04-27 2014-11-18 ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法

Country Status (9)

Country Link
US (2) US20120010170A1 (cg-RX-API-DMAC7.html)
EP (1) EP2155257B1 (cg-RX-API-DMAC7.html)
JP (2) JP2010525063A (cg-RX-API-DMAC7.html)
CN (2) CN101678122A (cg-RX-API-DMAC7.html)
AU (1) AU2008246195B2 (cg-RX-API-DMAC7.html)
CA (1) CA2685285A1 (cg-RX-API-DMAC7.html)
ES (1) ES2609095T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009011573A (cg-RX-API-DMAC7.html)
WO (1) WO2008133966A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110655A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
CN105055432A (zh) 2008-01-25 2015-11-18 奇默里克斯公司 治疗病毒感染的方法
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
WO2011017253A1 (en) * 2009-08-03 2011-02-10 Chimerix, Inc. Composition and methods of treating viral infections and viral induced tumors
CN102665729A (zh) * 2009-10-30 2012-09-12 奇默里克斯公司 用于治疗病毒相关性疾病的方法
AU2010313273B2 (en) * 2009-10-30 2015-04-02 Emergent Biodefense Operations Lansing Llc Methods of treating viral associated diseases
CA2789443C (en) 2010-02-12 2016-09-13 Chimerix, Inc. Nucleoside phosphonate salts
EP2563367A4 (en) 2010-04-26 2013-12-04 Chimerix Inc Methods of treating retroviral infections and related dosage regimes
AU2015201895B2 (en) * 2010-08-31 2016-11-17 Emergent Biodefence Operations Lansing Llc Phosphonate ester derivatives and methods of synthesis thereof
CN105998039A (zh) * 2010-08-31 2016-10-12 奇默里克斯公司 膦酸酯衍生物及其合成方法
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
CA2857490C (en) 2011-12-22 2020-03-31 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
US20140011769A1 (en) * 2012-07-03 2014-01-09 Chimerix, Inc. Methods of Treating Retroviral Infections and Related Dosage Regimes
KR20150130355A (ko) 2013-03-15 2015-11-23 더 리전트 오브 더 유니버시티 오브 캘리포니아 비환식 뉴클레오사이드 포스포네이트 디에스테르
UA116825C2 (uk) 2013-11-15 2018-05-10 Чимерикс Інк. Морфологічні форми гексадецилоксипропілових складних ефірів фосфонової кислоти і способи їх синтезу
MX377983B (es) 2014-09-15 2025-03-04 Univ California Análogos de nucleótidos.
EP3875462A1 (en) 2015-09-15 2021-09-08 The Regents of The University of California Nucleotide analogs
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
AU2017290703B2 (en) * 2016-06-28 2023-03-30 Emergent Biodefense Operations Lansing Llc Formulations of brincidofovir
WO2018156879A1 (en) * 2017-02-23 2018-08-30 Chimerix, Inc. Treatment of adenovirus with brincidofovir
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
AU2022256476B2 (en) 2021-04-16 2025-06-05 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
KR20250052378A (ko) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716825B2 (en) * 1999-12-03 2004-04-06 The Regents Of The University Of California Phosphonate compounds
KR20050048539A (ko) * 2001-10-06 2005-05-24 메리얼엘엘씨 CpG 제제 및 관련된 방법
WO2006110655A2 (en) * 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
CN100396689C (zh) * 2006-03-07 2008-06-25 中国医学科学院医药生物技术研究所 一组具有抑制hiv-1/hbv病毒复制活性的替诺福韦单酯化合物

Similar Documents

Publication Publication Date Title
JP2013509433A5 (cg-RX-API-DMAC7.html)
Kim et al. Coinfection with HIV-1 and HCV—a one-two punch
Waggoner et al. Roles of natural killer cells in antiviral immunity
De Clercq Antivirals: past, present and future
RU2015141024A (ru) Производные эфиров фосфоновых кислот и способы их синтеза
De Clercq Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections
De Clercq et al. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy) alkoxy]-2, 4-diaminopyrimidines
Israely et al. A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease
MX2010008148A (es) Métodos de tratamiento de infecciones virales.
HRP20230274T1 (hr) Kemijski spojevi
MA33449B1 (fr) Antigènes recombinants du vrs
WO2007038507A3 (en) Modified 4'-nucleosides as antiviral agents
JP2013503882A5 (cg-RX-API-DMAC7.html)
JP2013510091A5 (cg-RX-API-DMAC7.html)
RU2011127080A (ru) Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич
CN111265508A (zh) 双醋瑞因在制备抗病毒药物及治疗病毒感染中的用途
DK200300015A (da) Anvendelse af stammer af Parapoxvirus ovis til fremstilling af antivirale lægemidler og lægemidler mod cancer
WO2007137591A3 (en) Hiv vaccine
WO2018005909A1 (en) Combinations and uses and treatments thereof
Krause et al. Safety of viral DNA in biological products
JP2021046360A5 (cg-RX-API-DMAC7.html)
WO2006045616A3 (en) β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES
De Clercq Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES)
Actor Clinical virology
Andrei et al. Cidofovir and Brincidofovir